ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Trastuzumab

Also written as “Herceptin”, “trastuzumab [Herceptin]” and “trastuzumab”.

Its studies are mostly in Breast Neoplasms · Stomach Neoplasms · Colorectal Neoplasms · Neoplasms · Urologic Neoplasms, led by 20 companies.

Drug pageTrastuzumab: every studyMany companies study it; this page follows only the 79 they lead. All 533 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 13, 201079 company-led studies, 4 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche470 open or runningphase 4since Dec 13, 2010May 2, 2000none ahead
Novartisits history only50 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
Pfizerits history only31 open or runningphase 3since Feb 14, 2022Oct 20, 2005Dec 31, 2027phase 3 · NCT05253651
Celltrionits history only20 open or runningphase 3since Jun 11, 2014Jun 11, 2014none ahead
GlaxoSmithKlineits history only20 open or runningphase 2since Aug 31, 2007Aug 31, 2007none ahead
Jiangsu HengRui Medicineits history only22 open or runningphase 3since Aug 14, 2026Aug 17, 2025Oct 2027phase 2 · NCT07140393
Prestige Biopharmaits history only20 open or runningphase 3since Dec 29, 2016Dec 29, 2016none ahead
Sanofiits history only20 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Sarah Cannon Research Instituteits history only21 open or runningphase 2since Jun 27, 2007Jun 27, 2007none ahead
Tanvex BioPharma USAits history only20 open or runningphase 3since Jun 1, 2018Jun 1, 2018none ahead

Also a collaborator on its studies: Daiichi Sankyo, Medivation LLC, a wholly owned subsidiary of Pfizer, AbbVie, Zai Lab, Nippon Kayaku, MDS Pharma Services, Mylan and Dong-A Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 30 studies since May 2, 2000.

  1. Nov 25, 2013Phase 3 study in Breast NeoplasmsNCT01998906 · 330 enrolled · Austria, Germany, Italy and more
  2. Dec 3, 20134 phase 2 studiesNCT02015676, NCT02013765, NCT02005484 and 1 more
  3. Dec 18, 2013Phase 3 study in Breast NeoplasmsNCT02019277 · 50 enrolled · Australia
  4. Jan 15, 2014Phase 3 study in Breast NeoplasmsNCT02040935 · 128 enrolled · Netherlands
  5. Mar 17, 2014Phase 2 study in NeoplasmsNCT02091141 · 673 enrolled · United States
  6. May 6, 2014Phase 2 study in Breast NeoplasmsNCT02132949 · 401 enrolled · United States, Canada, Denmark and more
  7. Jul 8, 2014Phase 3 study in Breast NeoplasmsNCT02194166 · 90 enrolled · Belarus, Kazakhstan
  8. Nov 11, 2014Phase 2 study in Colorectal NeoplasmsNCT02291289 · 1,044 enrolled · Argentina, Belgium, Bosnia and Herzegovina and more
  9. Mar 23, 2015Phase 4 study in Breast NeoplasmsNCT02419742 · 110 enrolled · India
  10. Mar 23, 2015Phase 3 study in Breast NeoplasmsNCT02402712 · 418 enrolled · Belgium, Bulgaria, Canada and more
  11. Aug 10, 2015Phase 2 study in Breast NeoplasmsNCT02536339 · 40 enrolled · United States
  12. Mar 24, 2016Phase 3 study in NeoplasmsNCT02721641 · 69 enrolled · Australia, Belgium, China and more
  13. Apr 20, 2016Phase 2 study in Breast NeoplasmsNCT02748213 · 225 enrolled · Australia, Brazil, Canada and more
  14. Jun 9, 2016Named trastuzumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HD201
  15. Oct 6, 2025Phase 1 study in Healthy ParticipantsNCT07214766 · 331 enrolled · United States

TargetBeta

ERBB2 →read by rule
“A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2)”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
pertuzumabruleHoffmann-La Rochephase 457
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 47 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07214766Healthy Participants · United States1CompletedJul 3, 2026331
NCT02748213Breast Neoplasms · Australia, Brazil, Canada and more2CompletedMar 2006225
NCT02721641Neoplasms · Australia, Belgium, China and more3CompletedFeb 201569
NCT02536339Breast Neoplasms · United States2CompletedMay 1, 201940
NCT02419742Breast Neoplasms · India4CompletedJun 24, 2021110
NCT02402712Breast Neoplasms · Belgium, Bulgaria, Canada and more3CompletedFeb 22, 2019418
NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more2CompletedMay 31, 20191,044
NCT02194166Breast Neoplasms · Belarus, Kazakhstan3CompletedJul 12, 201890
NCT02132949Breast Neoplasms · United States, Canada, Denmark and more2CompletedMar 3, 2016401
NCT02091141Neoplasms · United States2CompletedMay 24, 2023673
NCT02040935Breast Neoplasms · Netherlands3CompletedSep 14, 2018128
NCT02019277Breast Neoplasms · Australia3CompletedNov 4, 201650
NCT02006667Urologic Neoplasms · Germany2CompletedJan 201013
NCT02005484Stomach Neoplasms · Austria, Germany2TerminatedFeb 20086
NCT02015676Breast Neoplasms · Spain2CompletedSep 200969
NCT02013765Urologic Neoplasms · Germany2TerminatedJan 20105
NCT01998906Breast Neoplasms · Austria, Germany, Italy and more3CompletedJul 2012330
NCT01964391Breast Neoplasms · Algeria, Morocco, Saudi Arabia and more3CompletedDec 22, 2016174
NCT01940497Breast Neoplasms · Italy3CompletedApr 5, 2016240
NCT01928615Breast Neoplasms · Austria2TerminatedOct 20132
NCT01926886Breast Neoplasms · Belgium, Israel3CompletedSep 4, 2015102
NCT01810393Breast Neoplasms · France3CompletedJul 17, 2019114
NCT01748773Stomach Neoplasms · Turkey2CompletedAug 21, 201534
NCT01566721Breast Neoplasms · Albania, Algeria, Argentina and more3CompletedMar 10, 20152,577
NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more3TerminatedFeb 2015296
NCT01401166Breast Neoplasms · Canada, Denmark, France and more2CompletedMay 2013488
NCT01363986Breast Neoplasms · Italy2TerminatedJun 20123
NCT01344863Healthy Volunteer · New Zealand1CompletedJan 2012119
NCT01301729Breast Neoplasms · China4CompletedJul 201432
NCT01290718Breast Neoplasms · Taiwan2TerminatedDec 20124
NCT01260194Stomach Neoplasms · India4TerminatedJan 20154
NCT01130337Stomach Neoplasms · Spain2CompletedJun 201436
NCT01041404Stomach Neoplasms · Australia, Belgium, Brazil and more3CompletedJun 2010584
NCT00964704Breast Neoplasms2WithdrawnAug 20130
NCT00950300Breast Neoplasms · Argentina, Brazil, Canada and more3CompletedJul 12, 2011596
NCT00927589Solid Cancers · United States1CompletedFeb 201359
NCT00885755Breast Neoplasms · Australia, Spain, Sweden and more2CompletedFeb 18, 201333
NCT00811135Breast Neoplasms · Denmark, France, Russian Federation and more2CompletedDec 201588
NCT00800436Breast Neoplasms · Australia, New Zealand1CompletedOct 200966
NCT00717405Breast Neoplasms · France2CompletedApr 201052
NCT00545688Breast Neoplasms · Australia, Austria, Brazil and more2CompletedSep 22, 2014417
NCT00475670Breast Neoplasms · Australia, Austria, Belgium and more2CompletedJun 201244
NCT00448279Breast Neoplasms · Italy3CompletedSep 201058
NCT00444587Breast Neoplasms · Bulgaria, Estonia, Hungary and more2CompletedAug 2011114
NCT00045032Breast Neoplasms · Argentina, Australia, Austria and more3CompletedMar 20055,099
NCT00022672Breast Neoplasms · United States, Australia, Brazil and more3CompletedOct 2009208
NCT00005635Breast Neoplasms · United States2CompletedNov 2001

How it is read

Names in the registry

  • “Trastuzumab”, 36 entries
  • “Herceptin”, 13 entries
  • “trastuzumab [Herceptin]”, 11 entries
  • “trastuzumab”, 9 entries
  • “HD201”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.